Herzich Paul's most recent trade in Solid Biosciences Inc was a trade of 7,187 Common Stock done . Disclosure was reported to the exchange on Feb. 13, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 7,187 | 76,254 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2026 | 7,187 | 14,376 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 5.82 per share. | 13 Feb 2026 | 3,616 | 72,638 (0%) | 0% | 5.8 | 21,057 | Common Stock |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 04 Feb 2026 | 10,905 | 69,067 (0%) | 0% | 6.4 | 70,249 | Common Stock |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 170,000 | 170,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 85,000 | 85,000 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 54,925 | 81,547 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 54,925 | 0 | - | - | Performance Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2026 | 54,925 | 54,925 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 6.44 per share. | 29 Jan 2026 | 26,250 | 79,972 (0%) | 0% | 6.4 | 168,969 | Common Stock |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 24,675 | 74,025 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Jan 2026 | 24,675 | 106,222 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2025 | 7,239 | 29,323 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2025 | 7,239 | 7,239 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 5.11 per share. | 02 Dec 2025 | 2,701 | 26,622 (0%) | 0% | 5.1 | 13,802 | Common Stock |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 100,000 | 100,000 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Aug 2025 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 7,187 | 21,076 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 7,187 | 21,563 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 3.96 per share. | 13 Feb 2025 | 2,688 | 18,388 (0%) | 0% | 4.0 | 10,644 | Common Stock |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 98,700 | 98,700 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 7,239 | 14,959 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 7,239 | 14,478 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 5.60 per share. | 02 Dec 2024 | 2,777 | 12,182 (0%) | 0% | 5.6 | 15,551 | Common Stock |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 57,500 | 57,500 | - | - | Employee Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 28,750 | 28,750 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 7,238 | 21,717 | - | - | Restricted Stock Units | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2023 | 7,238 | 7,238 (0%) | 0% | - | Common Stock | |
| Solid Biosciences Inc | Herzich Paul | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 2.77 per share. | 02 Dec 2023 | 2,968 | 4,270 (0%) | 0% | 2.8 | 8,232 | Common Stock |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2022 | 57,900 | 57,900 | - | - | Stock Option (Right to Buy) | |
| Solid Biosciences Inc | Paul Herzich | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Dec 2022 | 28,955 | 28,955 | - | - | Restricted Stock Units |